company background image

Moderna NasdaqGS:MRNA Stock Report

Last Price


Market Cap







05 Oct, 2022


Company Financials +
MRNA fundamental analysis
Snowflake Score
Future Growth0/6
Past Performance6/6
Financial Health6/6

MRNA Stock Overview

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally.

Moderna, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Moderna
Historical stock prices
Current Share PriceUS$125.62
52 Week HighUS$376.65
52 Week LowUS$115.03
1 Month Change-9.35%
3 Month Change-27.14%
1 Year Change-58.46%
3 Year Change784.65%
5 Year Changen/a
Change since IPO575.38%

Recent News & Updates

Sep 28

Moderna gets EMA review for Omicron BA.4/BA.5 targeting booster shot for aged 12, above

The European Medicines Agency (EMA) accepted Moderna's (NASDAQ:MRNA) application for conditional marketing authorization of a 50 µg booster dose of the Omicron-containing bivalent COVID booster vaccine mRNA-1273.222 (Spikevax bivalent Original/Omicron BA.4-5) in adults 12 years and older. Spikevax bivalent Original/Omicron BA.4-5 is a next-generation bivalent vaccine that contains 25 µg of mRNA-1273 (Spikevax) and 25 µg of a vaccine targeting the Omicron variant BA.4/BA.5, Moderna said in a Sept. 28 press release. "Following the recent approval of our BA.1 targeting vaccine in Europe, our BA.4/BA5 Omicron targeting vaccine will now bring a second option to help protect people across Europe as we head into the winter months," said Moderna CEO Stéphane Bancel. MRNA +0.14% to $122.40 premarket Sept. 28

Sep 20

EMA aims to start review of Moderna's Omicron BA.4/5 adapted shot by end of September

The European drug regulator expects to start a review of Moderna's (NASDAQ:MRNA) Omicron-subvariant adapted vaccine by the end of this month. "Discussions are ongoing with Moderna in preparation for an application for a Spikevax BA.4/5 adapted bivalent vaccine," the European Medicines Agency's (EMA) Head of Biological Health Threats and Vaccines Strategy Marco Cavaleri said in a press briefing on Tuesday. The EMA has for now recommended approving Pfizer (PFE) and German partner BioNTech's (BNTX) BA.4/5 adapted COVID-19 vaccine, which it did last week. Moderna (MRNA) has so far received conditional marketing approvals in the European Union for its Spikevax COVID-19 vaccine targeting the original SARS-CoV-2 strain and a bivalent shot targeting the original strain and the Omicron BA.1 variant. The EMA has also recommended converting the conditional approvals for MRNA into standard marketing authorizations. Moderna (MRNA) stock +4.2% to $133.21 in morning trading.

Sep 14

Moderna CEO open to providing COVID shots to China; mulls building mRNA facility in Japan - Reuters

Moderna (NASDAQ:MRNA) CEO Stephane Bancel said that the company has discussed with the Chinese government about providing COVID-19 vaccines, but no decision has been reached, Reuters reported. Bancel declined to comment that if Moderna had filed for approval of the vaccine in China but noted that company was open to supplying and had the capacity, the report added. Bancel, who was speaking in Tokyo said that the company is also thinking of setting up facilities in Japan to manufacture mRNA-based products, the report added. On Sept. 12, Japan's Ministry of Health, Labour and Welfare approved Moderna's Omicron-targeting bivalent COVID-19 booster vaccine. Spikevax Bivalent Original/Omicron contains mRNA-1273 (Spikevax) and a vaccine candidate targeting the Omicron variant BA.1.

Shareholder Returns

MRNAUS BiotechsUS Market

Return vs Industry: MRNA underperformed the US Biotechs industry which returned -20.8% over the past year.

Return vs Market: MRNA underperformed the US Market which returned -18.2% over the past year.

Price Volatility

Is MRNA's price volatile compared to industry and market?
MRNA volatility
MRNA Average Weekly Movement8.8%
Biotechs Industry Average Movement11.1%
Market Average Movement6.9%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market2.8%

Stable Share Price: MRNA is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: MRNA's weekly volatility (9%) has been stable over the past year.

About the Company

20102,700Stephane Bancel

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics.

Moderna, Inc. Fundamentals Summary

How do Moderna's earnings and revenue compare to its market cap?
MRNA fundamental statistics
Market CapUS$49.16b
Earnings (TTM)US$14.06b
Revenue (TTM)US$23.00b


P/E Ratio


P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
MRNA income statement (TTM)
Cost of RevenueUS$6.51b
Gross ProfitUS$16.49b
Other ExpensesUS$2.44b

Last Reported Earnings

Jun 30, 2022

Next Earnings Date


Earnings per share (EPS)35.93
Gross Margin71.71%
Net Profit Margin61.12%
Debt/Equity Ratio0%

How did MRNA perform over the long term?

See historical performance and comparison